Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Wednesday, February 12th. Analysts expect Palatin Technologies to post earnings of ($0.42) per share for the quarter.
Palatin Technologies Trading Down 8.8 %
Shares of PTN stock opened at $0.96 on Tuesday. Palatin Technologies has a 1 year low of $0.68 and a 1 year high of $4.65. The firm has a market cap of $18.73 million, a price-to-earnings ratio of -0.48 and a beta of 0.87.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Palatin Technologies in a research note on Friday.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Further Reading
- Five stocks we like better than Palatin Technologies
- Election Stocks: How Elections Affect the Stock Market
- Merck: 4 No-Brainer Reasons to Buy This Dip
- How to Evaluate a Stock Before Buying
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
